Jay Parrish, Pretzel Therapeutics CEO (ARCH)

Fresh­ly baked: Pret­zel Ther­a­peu­tics takes out the oven mitts to drug dis­eases in the pow­er­house of the cell 

Af­ter help­ing co-found Vir Biotech­nol­o­gy and lead the biotech’s busi­ness de­vel­op­ment through the first few years, in­clud­ing a rare emer­gency use au­tho­riza­tion for a Covid-19 treat­ment, Jay Par­rish has found a new home at the pret­zel pow­er­house.

Fo­cused on the so-called pow­er­house of the cell, the mi­to­chon­dria, Pret­zel Ther­a­peu­tics emerged Mon­day with $72.5 mil­lion in Se­ries A back­ing from ARCH Ven­ture Part­ners and Mubadala Cap­i­tal, along with a syn­di­cate of oth­er in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.